Option chain shows key data for MediPharm Labs's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for MediPharm Labs.

MediPharm Labs (OTC:MEDIF) Stock, Option Chain

MediPharm Labs

MediPharm Labs Corp is a pharmaceutical company specializing in precision-based cannabinoids. The Company operates in one reportable segment, the production and sales of cannabis flower, extracts, and derivative products. Through its wholesale and white-label platforms, MediPharm Labs formulates, develops, processes, packages, and distributes cannabis extracts and cannabinoid-based products to domestic and international markets. Geographically the company has a presence in Canada, Australia, Germany, and other countries and the majority of revenue derives from Canada.

pepi-stojanovski-MJSFNZ8BAXw-unsplash(1)

Cannabis

Earnings

News

MEDIF

TSX:LABS

CBD-based pharmaceutical company MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) announced on Thursday its third quarter financial results for the three months ended Sept. 30, 2024.&#34;Q3 2024 was a major step in the right direction towards profitability,&#34; Greg Hunter, the company&#39;s CFO, said. &#34;Paying off our debt and rationalizing facilities, pursuing cost efficiencies while growing our higher margin international revenues are all critical elements to position us for long-term sustainable growth.&#34;

CBD Pharma Co. MediPharm: 37% Increase In Q3 International Sales, 15% YoY Revenue Growth

elsa-olofsson-FkfIPqqv2Oc-unsplash(19)

Cannabinoids-focused pharmaceutical company MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) announced on Wednesday financial results for the second quarter ended June 30, 2024, revealing an 8% year-over-year and 6% sequential increase to CA$10.3 million ($7.5 million). &#34;We are very pleased with our Q2 results, showcasing substantial improvements in both revenue and profitability,&#34; David Pidduck, the company&#39;s CEO, said. &#34;The strategic initiatives implemented, including cost reductions and operational efficiencies, are yielding positive results. We are particularly encouraged by the continued growth in our international sales and the progress in innovation of non-combustible cannabis formats.&#34;

MediPharm Q2 Loss Narrows, Adjusted EBITDA Climbs As Gross Profit Improves Nearly 300% YoY

finance and marijuana (Kindel Media by Pexels)(22)

Exclusives

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CSE:VEXT

TSX:XLY

VEXTF

Select Sector SPDR-Consumer Discretionary

Vext Science, Inc. (CSE: VEXT) (OTCQX: VEXTF), a cannabis operator with vertical operations in Arizona and Ohio, said it will release its financial results for the second quarter ended June 30, 2024, before the market opens on Tuesday, Aug. 20, 2024. A conference call and webcast will take place on the same day at 08:00 am Eastern Time. Auxly Cannabis Group Inc. (TSX: XLY) (OTCQB: CBWTF) will report earnings results for its second quarter ended June 30, 2024, on Thursday, Aug. 15, 2024, before the financial markets open.Cannabinoids-focused MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) will release its second quarter financial results for the period ended June 30, 2024, before markets open on Wednesday, Aug. 14, 2024. A conference call and audio webcast will take place the same day at 8:30 am Eastern Time.

This Cannabis Co With Significant Growth Potential And Other Hot Weed Stocks Soon To Report Earnings, What Investors Need To Know Now

MEDIPHARM LABS CORP by Medipharm Labs Corporation

MediPharm Labs Corp

Medifast Inc

<p>In the last three months, 4 analysts have published ratings on Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $124.0, a high estimate of $132.00, and a low estimate of $100.00. This current average has increased by 14.29% from the previous average price target of $108.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740175266_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Intra-Cellular Therapies by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$132.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$132.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$132.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Hold</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Intra-Cellular Therapies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Intra-Cellular Therapies compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Intra-Cellular Therapies's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Intra-Cellular Therapies's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ITCI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Intra-Cellular Therapies analyst ratings.</strong></a></p>
<h2>Get to Know Intra-Cellular Therapies Better</h2>
<p>Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.</p>
<h3>Understanding the Numbers: Intra-Cellular Therapies's Finances</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Intra-Cellular Therapies showcased positive performance, achieving a revenue growth rate of <strong>39.23%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Intra-Cellular Therapies's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-15.03%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-2.3%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-1.99%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Intra-Cellular Therapies's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.02</strong>.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

ITCI

Intra-Cellular Therapies Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

<p>Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) in the last three months.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $17.38, a high estimate of $18.50, and a low estimate of $15.00. Marking an increase of 9.79%, the current average surpasses the previous average price target of $15.83. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740175259_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Pediatrix Medical Group. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>A.J. Rice</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$18.50</td>
<td>$16.50</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$18.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$15.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Tao Qiu</td>
<td>Macquarie</td>
<td>Announces</td>
<td>Outperform</td>
<td>$18.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Pediatrix Medical Group. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Pediatrix Medical Group compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Pediatrix Medical Group's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Pediatrix Medical Group's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Pediatrix Medical Group analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Discovering Pediatrix Medical Group: A Closer Look</h2>
<p>Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment and generates majority of the revenue through neonatology and other pediatric subspecialties.</p>
<h3>Key Indicators: Pediatrix Medical Group's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Pediatrix Medical Group's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>0.9%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Pediatrix Medical Group's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>3.8%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Pediatrix Medical Group's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>2.7%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Pediatrix Medical Group's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>0.95%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Pediatrix Medical Group's debt-to-equity ratio is below the industry average at <strong>0.93</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Beyond The Numbers: 4 Analysts Discuss Pediatrix Medical Group Stock

<p>In the latest quarter, 4 analysts provided ratings for ESAB (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESAB#NYSE">ESAB</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $137.25, with a high estimate of $160.00 and a low estimate of $125.00. Marking an increase of 3.98%, the current average surpasses the previous average price target of $132.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740175246_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive ESAB. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$133.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$125.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$131.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Saree Boroditsky</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$160.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to ESAB. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ESAB compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of ESAB's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of ESAB's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ESAB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on ESAB analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind ESAB</h2>
<p>ESAB, spun off from Colfax in 2022, is a leading manufacturer of equipment and consumables used in welding, cutting, and joining applications. Alongside competitors Lincoln Electric and ITW's Miller brand, ESAB is one of the top three players in the welding space. ESAB generated roughly $2.8 billion in revenue in 2023.</p>
<h3>Unraveling the Financial Story of ESAB</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Negative Revenue Trend:</strong> Examining ESAB's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately <strong>-1.14%</strong> in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> ESAB's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>10.14%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>3.85%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> ESAB's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>1.7%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>0.64</strong>, caution is advised due to increased financial risk.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ESAB

Forecasting The Future: 4 Analyst Projections For ESAB

<p>Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Builders FirstSource (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLDR#NYSE">BLDR</a>) in the last three months.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Builders FirstSource and provided 12-month price targets. The average target is $181.88, accompanied by a high estimate of $230.00 and a low estimate of $162.00. This current average has decreased by 9.58% from the previous average price target of $201.14. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740175236_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Builders FirstSource by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Dahl</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$162.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Keith Hughes</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$180.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Charles Perron-Piche</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$180.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Reuben Garner</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$170.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Sam Darkatsh</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$170.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Matthew Bouley</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$188.00</td>
<td>$211.00</td>
</tr>
<tr>
<td>W. Andrew Carter</td>
<td>Stifel</td>
<td>Announces</td>
<td>Buy</td>
<td>$175.00</td>
<td>-</td>
</tr>
<tr>
<td>Jay McCanless</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$230.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Builders FirstSource. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Builders FirstSource compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Builders FirstSource's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Builders FirstSource's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BLDR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Builders FirstSource analyst ratings.</strong></a></p>
<h2>Delving into Builders FirstSource's Background</h2>
<p>Builders FirstSource Inc is a manufacturer and supplier of building materials. The company offers structural and related building products such as factory-built roof and floor trusses, wall panels and stairs, vinyl windows, custom millwork and trim, and engineered wood. The products can be designed for each home individually and are installed by Builders FirstSource. The company's construction-related services include professional installation, turn-key framing, and shell construction. Builders FirstSource's customers range from large production builders to small custom homebuilders.</p>
<h3>Builders FirstSource: A Financial Overview</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Revenue Challenges:</strong> Builders FirstSource's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately <strong>-6.66%</strong>. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.</p>
<p><strong>Net Margin:</strong> Builders FirstSource's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>6.73%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>6.51%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Builders FirstSource's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>2.63%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Builders FirstSource's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>0.98</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BLDR

Where Builders FirstSource Stands With Analysts

<p>During the last three months, 6 analysts shared their evaluations of Sonoco Prods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SON#NYSE">SON</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Sonoco Prods and provided 12-month price targets. The average target is $61.17, accompanied by a high estimate of $71.00 and a low estimate of $50.00. Experiencing a 0.7% decline, the current average is now lower than the previous average price target of $61.60. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740175227_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A clear picture of Sonoco Prods's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Roxland</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$60.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Anthony Pettinari</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$55.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>George Staphos</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$71.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Gabe Hajde</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$50.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Michael Roxland</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$68.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Michael Roxland</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$63.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sonoco Prods. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sonoco Prods compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Sonoco Prods's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Sonoco Prods's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SON/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Sonoco Prods analyst ratings.</strong></a></p>
<h2>All You Need to Know About Sonoco Prods</h2>
<p>Over its 100-year-plus history, Sonoco Products has steadily assembled a diverse portfolio of industrial and consumer packaging product offerings such as flexible and rigid plastics, reels and spools, pallets, and composite cans. The company serves a variety of consumer and industrial end markets throughout North America. Sonoco has raised its dividend each year for more than 40 years.</p>
<h3>Unraveling the Financial Story of Sonoco Prods</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Sonoco Prods's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately <strong>-18.65%</strong>. This indicates a decrease in the company's top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-3.15%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-1.8%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Sonoco Prods's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-0.4%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Sonoco Prods's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>3.19</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Expectations For Sonoco Prods's Future

<p>Analysts' ratings for Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Sabra Health Care REIT and provided 12-month price targets. The average target is $19.25, accompanied by a high estimate of $20.00 and a low estimate of $17.00. Observing a downward trend, the current average is 0.41% lower than the prior average price target of $19.33. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740175216_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Sabra Health Care REIT by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Carletti</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Michael Lewis</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$17.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Aaron Hecht</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$20.00</td>
<td>-</td>
</tr>
<tr>
<td>Vikram Malhotra</td>
<td>Mizuho</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sabra Health Care REIT. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sabra Health Care REIT compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Sabra Health Care REIT's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Sabra Health Care REIT's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SBRA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Sabra Health Care REIT analyst ratings.</strong></a></p>
<h2>All You Need to Know About Sabra Health Care REIT</h2>
<p>Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.</p>
<h3>Sabra Health Care REIT's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Sabra Health Care REIT showcased positive performance, achieving a revenue growth rate of <strong>11.6%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> Sabra Health Care REIT's net margin excels beyond industry benchmarks, reaching <strong>25.61%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Sabra Health Care REIT's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>1.7%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Sabra Health Care REIT's ROA excels beyond industry benchmarks, reaching <strong>0.88%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.89</strong>, Sabra Health Care REIT adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


SBRA

A Glimpse Into The Expert Outlook On Sabra Health Care REIT Through 4 Analysts

<p>Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) has outperformed the market over the past 15 years by 2.13% on an annualized basis producing an average annual return of 13.97%. Currently, Stryker has a market capitalization of $146.06 billion. </p>
<p><strong>Buying $100 In SYK:</strong> If an investor had bought $100 of SYK stock 15 years ago, it would be worth <strong>$720.87</strong> today based on a price of $382.78 for SYK at the time of writing.</p>
<h3>Stryker's Performance Over Last 15 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740175213_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Trading Ideas

If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today

<p>Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) has outperformed the market over the past 5 years by 10.15% on an annualized basis producing an average annual return of 24.07%. Currently, Deere has a market capitalization of $133.45 billion. </p>
<p><strong>Buying $100 In DE:</strong> If an investor had bought $100 of DE stock 5 years ago, it would be worth <strong>$285.10</strong> today based on a price of $489.98 for DE at the time of writing.</p>
<h3>Deere's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740174309_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$100 Invested In Deere 5 Years Ago Would Be Worth This Much Today

<p>&nbsp;</p>
<p>reAlpha Tech Corp. (the "Company") has estimated its total revenue for the three months ended December 31, 2024, to be in the range of approximately $0.5 million to $0.6 million. The Company's estimated total revenue for the year ended December 31, 2024, is projected to be in the range of approximately $0.9 million to $1.0 million.</p>
<p>&nbsp;</p>
<p>The Company had cash of approximately $3.1 million as of December 31, 2024, a decrease of approximately $3.9 million from approximately $7.0 million as of September 30, 2024. This decrease in cash was primarily due to the Company's cash payment of $1.5 million to the sellers of Debt Does Deals, LLC, d/b/a Be My Neighbor ("BMN"), on October 1, 2024, and the Company's increased operating expenses related to BMN following its acquisition.</p>
<p>&nbsp;</p>
<p>This preliminary unaudited financial data has been prepared by, and is the responsibility of, the Company's management and is based on preliminary and unaudited information currently available to the Company as well as management's estimates as of the date of this Current Report on Form 8-K. The Company's actual financial results may differ materially from the estimated preliminary unaudited financial data set forth above and will not be finalized until after the Company completes its normal year-end accounting procedures. As a result, no undue reliance should be placed on these preliminary estimates. GBQ Partners, LLC ("GBQ"), the Company's independent registered public accounting firm, has not audited, reviewed, compiled or performed any procedures with respect to this estimated preliminary financial data. Accordingly, GBQ does not express an opinion or any other form of assurance with respect thereto.</p>


Guidance

AIRE

ReAlpha Tech Estimates Its Total Revenue For The Three Months Ended December 31, 2024, To Be In The Range Of ~$0.5M-$0.6M; Estimated Total Revenue For The Year Ended December 31, 2024, Is Projected To Be In The Range Of ~$0.9M-$1M

<p>Canaccord Genuity  analyst Katie Lachapelle   maintains Cameco (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CCO#TSX">CCO</a>) with a Buy and lowers the price target from C$85 to C$82.5.</p>


Price Target

TSX:CCO

Canaccord Genuity Maintains Buy on Cameco, Lowers Price Target to C$82.5

<p>Canaccord Genuity  analyst Dalton Baretto   maintains Teck Resources (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TECK#TSX">TECK</a>) with a Buy and raises the price target from C$71 to C$72.</p>


TSX:TECK

TSX:TECK/B

Canaccord Genuity Maintains Buy on Teck Resources, Raises Price Target to C$72

NKLA

Nikola Will Not Appeal Nasdaq Delisting Decision; Stock Trading To Be Suspended On Feb 26, 2025

WIIM

Nikola shares are trading lower after the company announced it received a delisting letter from the Nasdaq.

<p>Let's be real—retirement savings can feel like a giant, moving target. You hear numbers tossed around, but what does it actually take to retire comfortably if you're making $100,000, $150,000, or even $200,000 a year? If you&#8217;re <a href="https://www.benzinga.com/personal-finance/25/02/43759794/are-you-a-top-1-earner-heres-what-you-need-to-rake-in-to-be-among-the-richest">earning six figures</a>, you know the lifestyle you want isn't cheap.&nbsp;</p>
<p>Are you on track or is it time to kick your savings into high gear?</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong>The average 401(k) balance soars to a record-breaking high – <a href="https://www.benzinga.com/money/average-401k-balances-soars-to-record-high"><strong>Here's how to know if your nest egg is keeping pace.</strong></a></strong></li>
<li><strong>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"><strong> </strong><strong>here&#8217;s a breakdown on what&#8217;s behind this formula.</strong></a></strong></li>
</ul>
<h2 class="wp-block-heading">Retirement Savings Benchmarks for High Earners</h2>
<p><a href="https://www.edwardjones.com/us-en/market-news-insights/investor-education/investment-age/average-retirement-savings-age">According to Edward Jones</a>, here are generalized retirement savings goalposts based on age and salary:</p>
<p><strong>Ages 40-44:</strong></p>
<ul>
<li>$100,000 salary: $245,000 &#8211; $420,000</li>
<li>$150,000 salary: $490,000 &#8211; $795,000</li>
<li>$200,000 salary: $810,000 &#8211; $1,255,000</li>
</ul>
<p><strong>Ages 45-49:</strong></p>
<ul>
<li>$100,000 salary: $450,000 &#8211; $565,000</li>
<li>$150,000 salary: $840,000 &#8211; $1,040,000</li>
<li>$200,000 salary: $1,325,000 &#8211; $1,615,000</li>
</ul>
<p><strong>Ages 50-54:</strong></p>
<ul>
<li>$100,000 salary: $500,000 &#8211; $735,000</li>
<li>$150,000 salary: $920,000 &#8211; $1,320,000</li>
<li>$200,000 salary: $1,430,000 &#8211; $2,025,000</li>
</ul>
<p><strong>Ages 55-59:</strong></p>
<ul>
<li>$100,000 salary: $775,000 &#8211; $930,000</li>
<li>$150,000 salary: $1,385,000 &#8211; $1,650,000</li>
<li>$200,000 salary: $1,815,000 &#8211; $2,500,000</li>
</ul>
<p><strong>Ages 60-65:</strong></p>
<ul>
<li>$100,000 salary: $845,000 &#8211; $1,205,000</li>
<li>$150,000 salary: $1,490,000 &#8211; $2,110,000</li>
<li>$200,000 salary: $2,260,000 &#8211; $3,170,000</li>
</ul>
<p><strong>Trending: Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"><strong> The percentage may shock you</strong></a>.</strong></p>
<h2 class="wp-block-heading">Understanding These Numbers</h2>
<ul>
<li>$100,000 Earners: By 40, aim to have saved at least 2.5 times your salary, increasing to 12 times or more by 65.</li>
<li>$150,000 Earners: By 40, target around 3.3 times your salary, reaching 14 times or more by 65.</li>
<li>$200,000 Earners: Expect to have 4 times your salary saved by 40, growing to 16 times or more by 65 to maintain your high-income lifestyle.</li>
</ul>
<h2 class="wp-block-heading">Strategies to Stay on Track</h2>
<p>Financial guru Dave Ramsey provided some investment options for high-income earners in a&nbsp; Ramsey Solutions <a href="https://www.ramseysolutions.com/retirement/investment-options-for-high-income-earners">blog post</a> back in October. Some of the options mentioned where:&nbsp;</p>
<ol>
<li>Maximize Retirement Contributions: Utilize tax-advantaged accounts like 401(k)s and IRAs. For 2025, the contribution limits are $23,000 for 401(k)s and $7,000 for IRAs, with additional catch-up contributions if you're 50 or older.</li>
<li>Explore Backdoor Roth IRAs: High-income earners often exceed the income limits for direct Roth IRA contributions. However, a backdoor Roth IRA allows you to convert a traditional IRA into a Roth IRA, enabling tax-free growth and withdrawals in retirement. </li>
<li>Consider Health Savings Accounts (HSAs): If you have a high-deductible health plan, an HSA offers triple tax advantages: contributions are tax-deductible, growth is tax-free, and withdrawals for qualified medical expenses are tax-free. </li>
<li>Invest Beyond Traditional Accounts: Taxable brokerage accounts, real estate, and other assets can provide additional growth and income streams.</li>
<li>Monitor Lifestyle Inflation: Maintain a balance between enjoying your income and saving for the future. Avoid unnecessary lifestyle upgrades that can impede your savings goals.</li>
<li>Plan for Healthcare Costs: Healthcare can be a <a href="https://www.benzinga.com/personal-finance/24/12/42712291/438-billion-in-savings-and-335000-lives-what-it-would-cost-the-u-s-to-implement-universal-health-care">significant expense in retirement</a>. Consider long-term care insurance and continue contributing to HSAs to prepare for these costs.</li>
<li>Seek Professional Guidance: Regular <a href="https://www.benzinga.com/money/are-you-rich">consultations with a financial advisor</a> can help tailor your investment strategies to your goals and keep you informed about changes in tax laws and investment opportunities.</li>
</ol>
<p>Achieving a comfortable retirement requires proactive planning, especially for high earners. By setting <a href="https://www.benzinga.com/personal-finance/25/02/43473640/can-you-guess-the-average-retirees-net-worth-surprisingly-it-tends-to-skyrocket-during-retirement">clear savings targets</a> and exploring various investment avenues, you can work towards a financially secure future. Remember, the earlier you start and the more consistently you save and invest, the better positioned you'll be to enjoy your retirement years.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></strong></li>
<li><strong><a href="https://www.benzinga.com/money/millionaires-never-earned-six-figures-according-to-dave-ramsey">69% of Millionaires Never Earned A Six-Figure Salary – Here Are 2 Things They Do To Get Their First $1 Million, According To Dave Ramsey</a></strong></li>
</ul>


Personal Finance

Making Over $100,000 A Year? Here's How Big Your Retirement Nest Egg Should Be In Your 40s, 50s, And 60s If You Want To Retire Rich

<p>- Reuters Citing Court Decision/ G1 Website</p>


Legal

Global

Brazil Supreme Court Justice Moraes Orders Video-Sharing Platform Rumble To Be Blocked In Brazil

Nikola Received Letter From Nasdaq Notifying Co That Staff Had Determined That Co's Securities Will Be Delisted From Nasdaq

<p><a href="https://x.com/andrewfeinberg/status/1893048253244915802?s=12" title="https://x.com/andrewfeinberg/status/1893048253244915802?s=12">https://x.com/andrewfeinberg/status/1893048253244915802?s=12</a></p>


Macro Economic Events

Politics

Economics

General

'AP Sues 3 Trump Administration Officials, Citing Freedom Of Speech' - AP News

Trump Administration Asks Senior Commerce Dept Export Policy Official To Resign From Post

<ul>
<li>Favorable Hawaii Supreme Court Decision Provides Clarity Needed to Help Finalize Maui Tort Litigation Settlement</li>
<li>Definitive Settlement Agreements Reached in Maui Wildfire Tort Litigation</li>
</ul>


Hawaiian Electric Industries Says Definitive Settlement Agreements Reached In Maui Wildfire Tort Litigation

<p>Canaccord Genuity  analyst Joseph Vafi   maintains Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) with a Buy and lowers the price target from $120 to $100.</p>


Comments

MediPharm Labs

MediPharm Labs (MEDIF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga